Forte Biosciences Inc
FBRX27.590USD
-1.220-4.23%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
345.53M시가총액
손실P/E TTM
자세한 내용은 Forte Biosciences Inc 회사
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Inc 정보
종목 코드 FBRX
회사 이름Forte Biosciences Inc
상장일Apr 13, 2017
CEOWagner (Paul A)
직원 수14
유형Ordinary Share
회계 연도 종료Apr 13
주소3060 Pegasus Park Drive
도시DALLAS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호75247
전화13106186994
웹사이트https://www.fortebiorx.com/home/default.aspx
종목 코드 FBRX
상장일Apr 13, 2017
CEOWagner (Paul A)
Forte Biosciences Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Thu, Jan 22
마지막 업데이트: Thu, Jan 22
주주
주주 유형
주주
주주
비율
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
기타
46.64%
주주
주주
비율
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
기타
46.64%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
46.65%
Hedge Fund
32.83%
Private Equity
9.56%
Investment Advisor
7.51%
Corporation
2.86%
Individual Investor
1.11%
Research Firm
0.12%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
84
11.49M
91.73%
+522.83K
2025Q3
75
10.85M
55.60%
+222.21K
2025Q2
78
10.20M
43.87%
+4.95M
2025Q1
72
5.29M
79.85%
+32.05K
2024Q4
73
5.16M
31.17%
+3.22M
2024Q3
65
789.31K
58.51%
-26.11K
2024Q2
72
815.46K
58.79%
-11.24K
2024Q1
101
826.69K
59.45%
-38.71K
2023Q4
113
819.35K
60.39%
+5.27K
2023Q3
130
814.23K
49.33%
+164.66K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Fred Alger Management, LLC
1.64M
13.06%
+17.38K
+1.07%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
1.64M
13.05%
+156.73K
+10.60%
Sep 30, 2025
Janus Henderson Investors
1.40M
11.21%
+8.99K
+0.64%
Sep 30, 2025
OrbiMed Advisors, LLC
1.20M
9.56%
--
--
Sep 30, 2025
Affinity Asset Advisors LLC
840.00K
6.71%
+840.00K
--
Dec 17, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
566.74K
4.52%
+79.82K
+16.39%
Sep 30, 2025
Cable Car Capital LLC
500.00K
3.99%
--
--
Sep 30, 2025
Sphera Funds Management Ltd.
474.31K
3.79%
-20.80K
-4.20%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Alger 35 ETF
1.35%
Texas Capital Texas Small Cap Equity Index ETF
0.06%
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
비율1.35%
Texas Capital Texas Small Cap Equity Index ETF
비율0.06%
iShares Micro-Cap ETF
비율0.01%
Dimensional US Core Equity 1 ETF
비율0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
Fidelity Nasdaq Composite Index ETF
비율0%
Alger Mid Cap 40 ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
날짜
배당락일
유형
비율
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
